Skip Nav Destination
Issues
1 September 2000
ISSN 1078-0432
EISSN 1557-3265
Editorial
Editorials
Minireview
Advances in Brief
A Phase I Trial of a Human Papillomavirus (HPV) Peptide Vaccine for Women with High-Grade Cervical and Vulvar Intraepithelial Neoplasia Who Are HPV 16 Positive1
Laila Muderspach; Sharon Wilczynski; Linda Roman; Liz Bade; Juan Felix; L. A. Small; W. Martin Kast; Grace Fascio; Verna Marty; Jeffrey Weber
Clinical Trials
Phase III Evaluation of Octreotide versus Chemotherapy with 5-Fluorouracil or 5-Fluorouracil Plus Leucovorin in Advanced Exocrine Pancreatic Cancer: A North Central Cancer Treatment Group Study1
Patrick A. Burch; Margaret Block; Georgene Schroeder; John W. Kugler; Daniel J. Sargent; Theodore A. Braich; James A. Mailliard; John C. Michalak; Alan K. Hatfield; Keith Wright; Steven A. Kuross
Molecular Oncology, Markers, Clinical Correlates
Expression of Stromal Cell-derived Factor 1 and CXCR4 Ligand Receptor System in Pancreatic Cancer: A Possible Role for Tumor Progression
Takatomo Koshiba; Ryo Hosotani; Yoshiharu Miyamoto; Jun Ida; Shoichiro Tsuji; Sanae Nakajima; Michiya Kawaguchi; Hiroyuki Kobayashi; Ryuichiro Doi; Toshiyuki Hori; Nobutaka Fujii; Masayuki Imamura
Reliable and Sensitive Analysis of Occult Bone Marrow Metastases Using Automated Cellular Imaging
Kenneth D. Bauer; Jose de la Torre-Bueno; Ingo J. Diel; Debra Hawes; William J. Decker; Carl Priddy; Blaise Bossy; Susan Ludmann; Karen Yamamoto; Aneal S. Masih; Froilan P. Espinoza; Douglas S. Harrington
Experimental Therapeutics, Preclinical Pharmacology
Preclinical Study of the Systemic Toxicity and Pharmacokinetics of 5-Iodo-2-deoxypyrimidinone-2′-deoxyribose as a Radiosensitizing Prodrug in Two, Non-Rodent Animal Species: Implications for Phase I Study Design1
Timothy J. Kinsella; Jane E. Schupp; Thomas W. Davis; Suzanne E. Berry; Hwa-Shin Hwang; Kathy Warren; Frank Balis; John Barnett; Howard Sands
9-cis-Retinoic Acid Suppresses Mammary Tumorigenesis in C3(1)-Simian Virus 40 T Antigen-transgenic Mice1
Kendall Wu; Hee-Tae Kim; Jenny L. Rodriquez; Deborah Munoz-Medellin; Syed K. Mohsin; Susan G. Hilsenbeck; William W. Lamph; Marco M. Gottardis; Michael A. Shirley; John G. Kuhn; Jeff E. Green; Powel H. Brown
Co-administration of Probenecid, an Inhibitor of a cMOAT/MRP- like Plasma Membrane ATPase, Greatly Enhanced the Efficacy of a New 10-Deazaaminopterin against Human Solid Tumors in Vivo1
F. M. Sirotnak; H. Guido Wendel; William G. B. Bornmann; William P. Tong; Vincent A. Miller; Howard I. Scher; Mark G. Kris
Antiangiogenic and Antitumor Activity of Anti-Epidermal Growth Factor Receptor C225 Monoclonal Antibody in Combination with Vascular Endothelial Growth Factor Antisense Oligonucleotide in Human GEO Colon Cancer Cells1
Fortunato Ciardiello; Roberto Bianco; Vincenzo Damiano; Gabriella Fontanini; Rosa Caputo; Grazia Pomatico; Sabino De Placido; A. Raffaele Bianco; John Mendelsohn; Giampaolo Tortora
In Vitro and in Vivo Pharmacological Characterizations of the Antitumor Properties of Two New Olivacine Derivatives, S16020-2 and S30972-11
Hugues Malonne; Sophie Farinelle; Christine Decaestecker; Laurence Gordower; Jeanine Fontaine; Françoise Chaminade; Jean-Marie Saucier; Ghanem Atassi; Robert Kiss
Cancer Biology, Immunology, Cytokines
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.